Corbus Pharmaceuticals (NASDAQ:CRBP) Announces Earnings Results, Beats Expectations By $0.04 EPS

Corbus Pharmaceuticals (NASDAQ:CRBP) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.04, Fidelity Earnings reports. Corbus Pharmaceuticals had a negative return on equity of 139.91% and a negative net margin of 164.68%. The firm had revenue of $2.59 million during the quarter, compared to analysts’ expectations of $1.73 million.

Shares of NASDAQ CRBP traded up $0.08 during midday trading on Friday, hitting $4.59. The stock had a trading volume of 1,208,800 shares, compared to its average volume of 1,013,153. The firm has a market cap of $329.72 million, a P/E ratio of -4.68 and a beta of 1.87. The company’s 50-day simple moving average is $5.02 and its 200 day simple moving average is $6.11. Corbus Pharmaceuticals has a fifty-two week low of $4.19 and a fifty-two week high of $9.11. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.56 and a quick ratio of 2.56.

A number of equities research analysts recently weighed in on CRBP shares. Zacks Investment Research cut Corbus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday. BidaskClub raised Corbus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, October 22nd. ValuEngine cut Corbus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, August 2nd. Finally, Royal Bank of Canada reaffirmed a “buy” rating and set a $23.00 price target on shares of Corbus Pharmaceuticals in a report on Sunday, August 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. Corbus Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $23.71.

In other news, COO Robert Paul Discordia purchased 15,000 shares of the business’s stock in a transaction dated Monday, August 12th. The shares were bought at an average cost of $5.86 per share, for a total transaction of $87,900.00. Following the completion of the acquisition, the chief operating officer now directly owns 30,150 shares in the company, valued at approximately $176,679. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Over the last 90 days, insiders bought 19,175 shares of company stock worth $112,241. Corporate insiders own 8.20% of the company’s stock.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase 3 clinical trial for the treatment of systemic sclerosis and dermatomyositis, and in Phase 2 clinical trial to treat systemic lupus erythematosus and cystic fibrosis.

Featured Article: How does a security become overbought?

Earnings History for Corbus Pharmaceuticals (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit